Erratum to: Roxithromycin: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use

Davis, Rick; Brogden, Rex N.; Markham, Anthony; Faulds, Diana

doi:10.1007/bf03257478

Cited by 25 publications

(10 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a key antibiotic against Helicobacter pylori , the mean 90% minimal inhibitory concentration (MIC) of clarithromycin is 0.03mg/L. With the long postantibiotic effect (PAE), T > MIC, AUC/MIC, and the seriousness of infection, a clarithromycin dose of 250 or 500 mg bid is effective in “Western” adult patients, while the divided dose is lower in Japanese people . This may be on account of the lower BMI in Asian populations.…”

Section: Discussionmentioning

confidence: 99%

Half‐dose clarithromycin‐containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single‐center, open‐label, randomized trial

Wang

et al. 2019

Helicobacter

View full text Add to dashboard Cite

Background Clarithromycin‐containing bismuth quadruple therapy has been recommended as the first‐line therapy for H pylori infection in China. However, its expensive cost and high antibiotic‐related adverse reactions are always haunting us. To find a safer, more cost‐effective, and high eradicative strategy for Helicobacter treatment, we investigated the efficacy of 14‐day bismuth quadruple therapy and different doses of clarithromycin in the first‐line treatment. Method A total of 210 patients with H pylori infection were recruited and randomly assigned to half‐dose clarithromycin group (esomeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 250 mg bid, and bismuth potassium citrate 0.6 g bid) for 14 days or standard‐dose clarithromycin group (esomeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid, and bismuth potassium citrate 0.6 g bid) for 14 days. A 13C‐urea breath test (13C‐UBT) was performed at least 4 weeks after treatment. The eradication rate of H pylori, the incidence of side effects, and the cost‐effectiveness of regimens were evaluated in this study. Results The eradication frequencies were 86.67% for both groups in the intention‐to‐treat analysis, while the per‐protocol eradication rates were 91% vs. 91.92% (p=0.817). The incidence of adverse events was higher in standard dose group (54.21% vs. 34.29%; p=0.004), especially bitter taste symptom. There was a higher level of costs per person associated with the standard‐dose group as compared with half‐dose group (￥804.3 vs ￥654.36). The cost‐effectiveness ratio of the half dose was less than that of the standard dose (7.55 vs 9.16 CNY per percent). Conclusions A 14‐day half‐dose clarithromycin‐containing bismuth quadruple regimen is as effective as the standard bismuth quadruple therapy at eradicating H pylori, which is better tolerated and more economical. (ChiCTR‐ROC‐15007406).

show abstract

Section: Discussionmentioning

confidence: 99%

Half‐dose clarithromycin‐containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single‐center, open‐label, randomized trial

Wang

et al. 2019

Helicobacter

View full text Add to dashboard Cite

show abstract

“…Roxithromycin, a derivative of erythromycin, is characterised by high plasma, tissue and body fluid concentrations and a long half-life, permitting an extended dosage interval. 10 Clinical efficacy rates of 77-100% have been reported in non-comparative trials of roxithromycin in the treatment of SSSIs in a double-blind study. Roxithromycin 150 mg twice daily and doxycycline 200 mg once daily had a clinical efficacy that was comparable with erythromycin, amoxicillin/clavulanic acid and doxycycline.…”

Section: Macrolidesmentioning

confidence: 99%

“…Roxithromycin, a derivative of erythromycin, is characterised by high plasma, tissue and body fluid concentrations and a long half‐life, permitting an extended dosage interval 10 . Clinical efficacy rates of 77‐100% have been reported in non‐comparative trials of roxithromycin in the treatment of SSSIs in a double‐blind study.…”

Section: Managementmentioning

confidence: 99%

The Management of Skin and Skin Structure Infections in Children, Adolescents and Adults: A Review of Empiric Antimicrobial Therapy

Wilson

1998

Int J Clinical Practice

View full text Add to dashboard Cite

This article reviews the diagnosis and management of mild-to-moderate skin and skin structure infections in children, adolescents and adults in a general practice setting. Therapies reviewed are those in current use: penicillins; beta-Iactamase stable penicillins, including flucloxacillin, oxacillin, and amoxicillin-clavulanate; oral quinolones: macrolides; and oral cephalosporins. Consideration is given to duration of therapy, side-effect profile and compliance.

show abstract

“…Ciprofloxacin, a fluoroquinolone antibiotic with a pH of 3.7, is highly stable to heat and has a halflife of 4-6 h, with a narrow absorption window [14]. Ciprofloxacin has a wide range of therapeutic effects, including urinary tract infections, pneumonia, skin and soft tissue infection, and bone and joint infections, to mention a few [15]. It inhibits the bacterial DNA-separating enzymes DNA gyrase, type II topoisomerase, and topoisomerase IV [16].…”

Section: Introductionmentioning

confidence: 99%

Preliminary investigation of Ciprofloxacin-loaded microparticles for the treatment of bone diseases using coconut oil and shea butter

Akin-Ajani

Awe

Adediran

2023

German J. Pharm. Biomaterials

View full text Add to dashboard Cite

Conventional drug delivery systems have several limitations, including poor bioavailability and an inability to effectively transport antibiotics to the needed site of infection in the bone. A formulation of ciprofloxacin-loaded microparticles derived from coconut oil and shea butter was developed to enable a selective and targeted distribution of the broad-spectrum antibiotic. Solid microparticles (SM), a mixture of solid and liquid lipid (coconut oil), solid-liquid microparticles (SLM), or coconut oil alone; liquid microparticles (LM), loaded with ciprofloxacin using the hot homogenization technique, were formulated. Evaluation of the microparticulate formulations included testing for particle size, the efficacy of entrapment, antibacterial activity, and in vitro drug release. The size of the microparticles that were loaded with ciprofloxacin ranked SM (5.25 ± 2.50 -5.56 ± 2.01 μm) < SLM (7.94 ± 3.89 -7.98 ± 2.00 μm) < LM (15.5 ± 1.50 -20.29 ± 10.75 μm). The microparticulate formulations had an entrapment efficiency of 43.26% and 63.34% for the antibiotic ciprofloxacin. When tested against Staphylococcus aureus, all formulations exhibited good antibacterial activity; however, the microparticles generated from coconut oil and shea butter exhibited more significant antibacterial activity (zone of inhibition 24.0 ± 0.8 -39.5 ± 9.2 mm), in comparison to the other formulations. LM had the fastest ciprofloxacin release (t50 = 5.5 min), but the microparticles formed from shea butter had a higher cumulative release (t50 = 12.7 min) compared to that from the mixture (p>0.05). These findings were obtained from in vitro drug release studies. The Korsmeyer-Peppas model could account for every formulation using the Fickian Case I transport mechanism. Because of their increased antibacterial activity, size, ability to entrap drugs, and in vitro drug release, the ciprofloxacin-loaded microparticles made from cold-pressed coconut oil combined with shea butter have the potential to provide a more effective treatment for bone diseases.

show abstract

Erratum to: Roxithromycin: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use

Cited by 25 publications

References 100 publications

Half‐dose clarithromycin‐containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single‐center, open‐label, randomized trial

Half‐dose clarithromycin‐containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single‐center, open‐label, randomized trial

The Management of Skin and Skin Structure Infections in Children, Adolescents and Adults: A Review of Empiric Antimicrobial Therapy

Preliminary investigation of Ciprofloxacin-loaded microparticles for the treatment of bone diseases using coconut oil and shea butter

Contact Info

Product

Resources

About